Postpartum depression (PPD) is a common and disabling psychiatric condition with significant consequences for maternal functioning, infant development, and family well-being. Although psychotherapy and selective serotonin reuptake inhibitors (SSRIs) remain first-line treatments, their delayed onset of action limits effectiveness in individuals with moderate-to-severe illness, suicidality, or marked functional impairment. Over the past decade, advances in perinatal neurobiology have led to the development of rapid-acting interventions targeting gamma-aminobutyric acid (GABA)-A receptor modulation, most notably neuroactive steroids. Brexanolone is an intravenous formulation of allopregnanolone. It showed rapid antidepressant effects but required prolonged monitored infusion and presents substantial implementation challenges. More recently, zuranolone, which is an oral neuroactive steroid administered over 14 days, has expanded access to rapid-acting treatment while introducing safety considerations related to sedation, driving impairment, and lactation counseling. In parallel, electroconvulsive therapy (ECT) remains the most established rapid-acting intervention for severe postpartum mood disorders, while repetitive transcranial magnetic stimulation (rTMS) and ketamine-based approaches continue to evolve. This narrative review synthesizes the historical development, mechanistic rationale, clinical evidence, and real-world implementation considerations for rapid-acting treatments in PPD, emphasizing patient selection, safety monitoring, breastfeeding considerations, and integration into multidisciplinary perinatal care pathways to optimize outcomes and equity of access.

Postpartum depression, Neurosteroids, Brexanolone, Zuranolone, Electroconvulsive therapy, Rapid-acting antidepressants, Perinatal psychiatry, Gamma-aminobutyric acid modulation.

Postpartum depression (PPD) affects 10 to 20% of births globally. It is a leading contributor to maternal morbidity during the first year after delivery.[1] Untreated PPD is associated with impaired maternal-infant bonding, adverse cognitive and emotional outcomes in children, relationship disruption, and increased suicide risk.[2] Despite routine screening recommendations, substantial treatment gaps persist due to stigma, limited access to specialty mental health services, delayed pharmacologic response, and socioeconomic barriers.[3]

Psychotherapy and antidepressant medications remain the cornerstone of PPD management; however, these interventions frequently require four to eight weeks to achieve optimal benefit.[4] For individuals presenting with severe symptoms, psychosis, or suicidality, such delays may pose unacceptable clinical risk. Interest has intensified in treatments capable of producing faster antidepressant effects. Advances in perinatal neurobiology have highlighted the role of neuroactive steroids and gamma-aminobutyric acid (GABAergic) signaling in postpartum mood regulation, informing the development of targeted pharmacologic strategies.[5] This narrative review examines the evolution and current role of rapid-acting treatments for PPD, with emphasis on neuroactive steroids, while situating these therapies alongside established somatic interventions and emerging modalities. Practical considerations related to implementation, safety, lactation, and health-system integration are discussed to inform real-world clinical practice.

Historical context: Historically, PPD was conceptualized primarily as a psychosocial reaction to childbirth instead of a biologically mediated disorder. Early management focused on supportive counseling and antidepressant therapies extrapolated from non-perinatal populations.[6] Epidemiologic research and the development of validated screening tools, such as the Edinburgh Postnatal Depression Scale, facilitated systematic identification of postpartum mood disorders.[7] Subsequent neuroendocrine research identified abrupt postpartum declines in estrogen and progesterone, particularly the progesterone-derived neurosteroids allopregnanolone, a potent positive allosteric modulator of the GABA-A receptor.[8,9] Dysregulation of inhibitory neurotransmission and stress responsivity emerged as central mechanisms underlying postpartum mood vulnerability, supported by models of neurosteroid withdrawal and maladaptive GABAergic adaptation.[10] These advances culminated in the approval of brexanolone in 2019 as the first medication specifically indicated for PPD, followed by zuranolone in 2023 as the first oral, rapid-acting agent.[11,12]

A narrative review methodology was employed to synthesize current evidence on rapid-acting treatments for postpartum depression. Literature was identified through structured searches of PubMed and Google Scholar, along with a review of U.S. Food and Drug Administration labeling resources and professional society guidelines. Search terms included “postpartum depression,” “brexanolone,” “zuranolone,” “neuroactive steroids,” “electroconvulsive therapy,” “repetitive transcranial magnetic stimulation,” and “ketamine.”

Studies were considered for inclusion if they met one or more of the following criteria: (1) randomized controlled trials evaluating treatment efficacy in postpartum depression; (2) systematic reviews or meta-analyses relevant to perinatal populations; (3) clinical practice guidelines or consensus statements; (4) pharmacokinetic or lactation studies; or (5) high-quality observational studies with clinical relevance. Priority was given to randomized controlled trials, systematic reviews, guideline statements, pharmacokinetic studies, and regulatory documents published between 2000 and 2025. Reference lists of key articles were manually screened to identify additional relevant sources. Study selection was guided by relevance to postpartum populations, clinical applicability, and recency of evidence, with emphasis on high-quality and peer-reviewed data.

As a narrative review, this study does not follow formal systematic review protocols and is therefore subject to potential selection bias, including reliance on available published literature and author interpretation. Efforts were made to minimize bias by incorporating multiple data sources, prioritizing higher levels of evidence, and presenting a balanced synthesis of findings across therapeutic modalities.

Pathophysiologic rationale for rapid-acting neurosteroid treatments: The perinatal period is characterized by profound neuroendocrine shifts, including steep postpartum declines in progesterone and its neuroactive metabolite allopregnanolone.[8] Allopregnanolone enhances inhibitory neurotransmission through positive allosteric modulation of GABA-A receptors.[9] Altered neurosteroid dynamics and impaired GABAergic signaling are hypothesized to contribute to postpartum mood symptoms.[5] Restoration of GABA-A receptor modulation may therefore produce antidepressant effects more rapidly than traditional monoaminergic agents, a hypothesis supported by clinical trial findings.[5,9]

Neuroactive Steroids: Evidence and practical use:

• Brexanolone (Zulresso®) – intravenous allopregnanolone: Brexanolone is an intravenous formulation of allopregnanolone administered as a continuous infusion over 60 hours in a certified healthcare setting under a mandatory Risk Evaluation and Mitigation Strategy (REMS).[11] The U.S. FDA prescribing information highlights serious risks of excessive sedation and sudden loss of consciousness, necessitating continuous cardiorespiratory monitoring, pulse oximetry, and structured clinical assessments during waking hours throughout the infusion period.[11,13] Randomized controlled trials demonstrated rapid and clinically meaningful reductions in depressive symptom severity during or shortly after infusion, supporting brexanolone as an effective rapid-acting treatment for moderate-to-severe PPD.[11,14] Despite its robust efficacy signal, real-world utilization has been limited by significant logistical and infrastructural demands. The boxed warning related to profound sedation requires immediate interruption or discontinuation of the infusion if concerning symptoms arise, underscoring the need for specialized inpatient-level monitoring.[15] Brexanolone administration requires access to a REMS-certified facility, continuous infusion staffing, and coordinated logistical planning to address childcare needs, breastfeeding considerations, and family support during prolonged hospitalization.[14,16] These barriers likely contribute to underutilization despite demonstrated therapeutic benefit. Clinically, brexanolone may be most appropriate in situations where rapid symptom resolution is essential, oral therapy is not feasible, and illness severity warrants an intensive, closely monitored intervention within an inpatient or infusion-center setting.[10,14]
• Zuranolone (Zurzuvae®) – oral neuroactive steroid: Zuranolone is an oral neuroactive steroid and positive allosteric modulator of the GABA-A receptor approved for the treatment of PPD as a once-daily, 14-day course.[12] Unlike brexanolone, zuranolone does not require intravenous administration or prolonged inpatient monitoring, substantially improving feasibility and scalability in outpatient and community-based settings.[11] Randomized, double-blind, placebo-controlled clinical trials demonstrated statistically significant and clinically meaningful reductions in depressive symptom severity, with symptom improvement observed as early as the first week of treatment and sustained beyond completion of the dosing period.[17,18] These findings support zuranolone as an effective, rapid-acting intervention for moderate-to-severe PPD.

The safety profile of zuranolone is characterized mainly by central nervous system (CNS) depressant effects, which include somnolence, dizziness, and fatigue.[12] The FDA prescribing information includes a boxed warning regarding impaired ability to drive or engage in other potentially hazardous activities, recommending that patients abstain from driving or operating heavy machinery for at least 12 hours after each dose throughout the treatment course.[12] This safety consideration has important implications for postpartum individuals responsible for infant care and transportation, necessitating proactive counseling and logistical planning before initiation. Concomitant use with alcohol, benzodiazepines, opioids, or other sedating medications may increase the risk of excessive sedation and should be carefully evaluated.[1]

• Breastfeeding considerations remain an area of evolving evidence. A dedicated lactation pharmacokinetic study demonstrated low concentrations of zuranolone in breast milk, with an estimated relative infant dose of less than 1% at the approved 50-mg dose, a threshold generally considered compatible with breastfeeding.[19,20] However, long-term infant outcome data are limited, and shared decision-making incorporating maternal symptom severity, infant health status, and patient preferences is essential.[20] In clinical practice, zuranolone may be particularly appropriate for patients requiring rapid symptom relief who are stable for outpatient treatment, prefer a short-duration therapy, or have had inadequate response or intolerance to conventional antidepressants, provided that structured safety monitoring and follow-up are in place.[11]

Other rapid-acting interventions in the postpartum period:

• ECT in PPD: ECT remains the most well-established and rapidly effective treatment for severe mood disorders in the postpartum period, including treatment-resistant PPD, depression with psychotic features, catatonia, and acute suicidality.[20-22] ECT has a long history of use in perinatal psychiatry and is supported by systematic reviews and observational studies demonstrating high response and remission rates, often exceeding those observed with pharmacologic interventions alone.[21,22] Unlike antidepressant medications, ECT can produce substantial symptom improvement within days, making it particularly valuable when immediate stabilization is required to protect maternal and infant safety.[22]

Importantly, ECT is considered compatible with breastfeeding, as anesthetic agents used during treatment have short half-lives and minimal transfer into breast milk, allowing breastfeeding to resume shortly after recovery from anesthesia.[20] This safety profile represents a critical advantage in the postpartum population. Adverse effects primarily include transient cognitive symptoms like short-term memory impairment and postictal confusion, which are typically reversible. Despite strong efficacy and safety data, ECT remains underutilized due to stigma, limited access, clinician and patient misconceptions, and delays in referral. From a clinical perspective, ECT should be considered early rather than as a last resort in cases of severe PPD where rapid symptom control is essential, and the risks of untreated illness outweigh potential treatment-related adverse effects.[20-22]

• Repetitive transcranial magnetic stimulation (rTMS): Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive neuromodulation therapy approved for the treatment of major depressive disorder and is being increasingly studied in perinatal populations. It alters cortical excitability by delivering targeted magnetic pulses to the dorsolateral prefrontal cortex, without requiring anesthesia or systemic medication exposure.[23] Preliminary studies and small clinical trials in PPD suggest that rTMS is feasible, well-tolerated, and associated with modest improvements in depressive symptoms.[23,24] The absence of systemic side effects and compatibility with breastfeeding make rTMS an appealing option for patients who prefer nonpharmacologic interventions or cannot tolerate medications.

However, the evidence base for rTMS in PPD remains limited compared with electroconvulsive therapy and neuroactive steroids. Most studies involve small sample sizes, heterogeneous stimulation protocols, and variable outcome measures, limiting generalizability.[24] Additionally, rTMS requires daily treatment sessions over several weeks, which may be logistically challenging for postpartum individuals due to childcare responsibilities, transportation demands, and insurance authorization barriers.[25]

• Ketamine/Esketamine: Ketamine and esketamine are established rapid-acting antidepressants in select clinical settings; however, postpartum-specific evidence remains limited. Recent meta-analyses suggest that ketamine and esketamine may reduce the incidence of postpartum depressive symptoms, particularly when administered around the time of cesarean delivery, although these benefits are accompanied by increased short-term adverse effects such as dizziness and perceptual disturbances.[26] A randomized clinical trial published in JAMA Network Open demonstrated that esketamine administered during cesarean delivery was associated with a reduced incidence of PPD at six weeks postpartum, while emphasizing the need for further investigation.[27] Importantly, existing studies largely address prevention in higher-risk or perioperative contexts rather than treatment of established moderate-to-severe PPD in outpatient psychiatric practice. From a clinical standpoint, ketamine and esketamine should currently be considered investigational or highly specialized options within PPD treatment pathways, requiring careful consideration of lactation exposure, dissociative effects, monitoring requirements, and regulatory or insurance constraints.[28,29]

Clinical implementation of rapid-acting treatments for PPD:
The successful translation of rapid-acting treatments for PPD into clinical practice requires structured, multidisciplinary care pathways that integrate screening, diagnostic confirmation, risk stratification, and longitudinal follow-up. Screening for depressive symptoms during pregnancy and the postpartum period is widely recommended; however, screening alone is insufficient without timely access to evidence-based treatment and continuity of care.[30] Patients presenting with postpartum depressive symptoms should undergo a comprehensive psychiatric evaluation, including assessment of symptom severity, suicidality, psychotic features, bipolar spectrum illness, substance use, and psychosocial stressors, as these factors critically influence treatment selection.[31]

For individuals with mild symptoms, psychotherapy and conventional antidepressants remain appropriate first-line interventions.[29] In contrast, patients with moderate-to-severe PPD, marked functional impairment, or inadequate response to standard therapies may benefit from rapid-acting options. Oral neuroactive steroid therapy with zuranolone represents a practical outpatient intervention when rapid symptom relief is needed, and the patient can adhere to safety requirements, including driving restrictions and avoidance of concomitant sedating substances.[16-18] Brexanolone may be considered when oral therapy is not feasible and adequate inpatient or infusion-center resources are available, particularly in cases where rapid symptom control is critical.[10,13]

Electroconvulsive therapy should be prioritized in cases of severe PPD with suicidality, psychotic features, catatonia, or treatment resistance, given its well-established efficacy and rapid onset of action.[20-22] Repetitive transcranial magnetic stimulation may be considered for patients who decline pharmacologic treatment or require a noninvasive option, although its delayed onset and logistical demands may limit feasibility in the immediate postpartum period.[23,24] Emerging treatments such as ketamine and esketamine currently remain investigational for established PPD and should be used cautiously within specialized settings.[26-28] To assess response, control side effects, address relapse risk and guarantee continuity of care beyond the early postpartum period, regular follow-up is crucial both during and after therapy, regardless of the strategy chosen. Optimizing mother and infant outcomes and minimizing inequalities in access to cutting-edge perinatal mental health therapies depend on the integration of psychiatric services with obstetric, paediatric, and breastfeeding care.[29,30]

Clinical implementation: From screening to sustained recovery:
The U.S. Preventive Services Task Force recommends routine screening of adults, including pregnant and postpartum individuals, for depression and suicide risk, while emphasizing that screening must be linked to diagnostic confirmation, effective treatment, and structured follow-up systems to improve outcomes.[3] Barriers to perinatal depression screening include time constraints, limited referral pathways, and inadequate access to mental health services for individuals who screen positive, representing an implementation gap that rapid-acting treatments alone cannot resolve.[29] Embedding a stepped-care model may facilitate timely escalation of care, beginning with systematic screening using validated instruments such as the Edinburgh Postnatal Depression Scale or PHQ-9, followed by risk stratification for suicidality, psychosis, bipolar spectrum illness, and substance use.[7,18] Treatment intensity can then be matched to clinical severity, ranging from psychotherapy and conventional antidepressants to neuroactive steroids or inpatient-level interventions such as electroconvulsive therapy when indicated.[4,10,20] Ongoing follow-up and relapse-prevention planning are essential components of this framework, ensuring continuity of care beyond initial symptom improvement and reducing the risk of recurrent PPD.[31]

Practical decision-making: Choosing among rapid-acting options:
Given the heterogeneity of PPD presentations and varying levels of clinical urgency, a structured and pragmatic decision-making framework is essential to guide the selection of rapid-acting interventions. Treatment choice should be individualized based on symptom severity, immediacy of risk, feasibility of monitoring, and patient preferences.[31] A pragmatic framework for selecting among rapid-acting treatments for PPD is summarized in Table 1.

Table 1: Pragmatic framework for selecting rapid-acting treatments for PPD

This framework is intended to support, rather than replace, clinical judgment and emphasizes shared decision-making, safety planning, and multidisciplinary collaboration. Regardless of the selected intervention, close follow-up and longitudinal care are critical to sustain treatment response and reduce relapse risk in the postpartum period.[31]

Counseling essentials for neurosteroid treatment:
Thorough counseling is essential when initiating neuroactive steroid therapy for PPD. For oral zuranolone, patients should be advised to abstain from driving or engaging in hazardous activities for at least 12 hours after each dose and to avoid alcohol and other central nervous system depressants with careful medication reconciliation before treatment initiation.[12,16] Given the risk of sedation, clinicians should collaborate with patients to develop an infant-care safety plan addressing nighttime feedings, co-sleeping, and supervision. Breastfeeding discussions should incorporate emerging data indicating low transfer of zuranolone into breast milk while acknowledging limited long-term infant outcome data and emphasizing individualized, shared decision-making.[18,19] Early follow-up, ideally within one week, is recommended to assess treatment response, safety, and adherence. For brexanolone, counseling should emphasize the requirement for administration in a REMS-certified setting with continuous monitoring due to the risk of excessive sedation and loss of consciousness.[11] Anticipatory guidance should address logistical demands of prolonged infusion, including childcare arrangements, identification of a support person, and lactation planning.[13]

Continuity of care and relapse prevention:
Although rapid-acting treatments can produce meaningful and timely symptom improvement, they do not eliminate relapse risk, underscoring the importance of comprehensive continuity-of-care planning. End-of-course management should include a clear transition strategy, such as continuation or intensification of psychotherapy and consideration of maintenance pharmacotherapy with an SSRI or serotonin–norepinephrine reuptake inhibitor in individuals with recurrent depression.[31] Attention to sleep stabilization and psychosocial support is critical given the bidirectional relationship between sleep disruption and mood symptoms in the postpartum period. Follow-up care should extend beyond the traditional 6-week obstetric window to ensure sustained symptom monitoring and treatment adjustment as needed. Coordination with pediatric and lactation services is particularly important when breastfeeding decisions are complex or evolving. Consistent with guidance from the American College of Obstetricians and Gynecologists, ongoing management should balance the risks of untreated maternal mental illness against potential medication exposure while emphasizing evidence-based pharmacotherapy, systematic monitoring, and multidisciplinary collaboration across pregnancy and the postpartum continuum.[15,30]

Comparing the treatment:
To contextualize the relative roles of available rapid-acting interventions for PPD, it is helpful to compare these modalities across key clinical dimensions, including route of administration, speed of symptom response, practical advantages, and implementation limitations. Neuroactive steroids such as brexanolone and zuranolone directly target postpartum-specific neurobiology and offer antidepressant effects within days, but differ substantially in feasibility and monitoring requirements.[10-18] Electroconvulsive therapy remains the most rapidly effective intervention for severe and life-threatening presentations, while noninvasive neuromodulation techniques and ketamine-based approaches occupy more selective or emerging roles.[20-27] Table 2 summarizes the principal characteristics of currently available rapid-acting treatments for PPD to support pragmatic, patient-centered decision-making in clinical practice.

Table 2: Comparison of rapid-acting treatments for PPD

The emergence of rapid-acting treatments has substantially reshaped the therapeutic landscape for PPD, addressing a long-standing clinical gap between symptom onset and meaningful treatment response. Traditional pharmacologic and psychotherapeutic approaches, while effective for many patients, often fail to provide the immediacy required in moderate-to-severe illness, particularly when functional impairment, suicidality, or psychotic features are present.[1,2] Advances in understanding postpartum neurobiology, specifically the role of neuroactive steroids and GABAergic modulation, have enabled the development of targeted interventions that align more closely with the pathophysiology of postpartum mood disorders.[5,8-10] Neuroactive steroids represent a paradigm shift in the treatment of PPD. Brexanolone established proof of concept by demonstrating that restoration of allopregnanolone signaling can produce rapid and sustained antidepressant effects.[10,11,14] However, its requirement for prolonged monitored intravenous infusion under a REMS program has limited widespread adoption, confining its use largely to specialized centers with sufficient infrastructure and resources.[11,13] Zuranolone extends this therapeutic advance by offering an oral, short-course alternative that enhances feasibility and scalability, particularly in outpatient settings.[11,17] Nevertheless, zuranolone introduces distinct safety considerations, including driving impairment and central nervous system depression, which necessitate structured patient counseling, medication reconciliation, and early follow-up to ensure safe implementation.[12,16-18]

Despite increasing excitement around new pharmacologic treatments, somatic therapies continue to play an important role in managing severe PPD. ECT remains the most effective and fastest-acting option for life-threatening conditions like psychotic depression and catatonia. It should be considered earlier in the treatment pathway instead of being reserved as a final option. [20-22] Repetitive transcranial magnetic stimulation offers a noninvasive alternative with favorable tolerability, although its delayed onset of benefit and logistical demands may limit its utility in the acute postpartum period.[23,24] Ketamine-based therapies, while promising in preventive contexts, require further investigation before routine adoption for established PPD.[26-28]

Implementation considerations are central to the real-world impact of rapid-acting treatments. Access to specialized care, insurance coverage, caregiving responsibility, and health system fragmentation all influence treatment feasibility and equity.[29,30] Without coordinated perinatal care pathways, novel therapies risk exacerbating existing disparities in maternal mental health outcomes.[29] Multidisciplinary collaboration among psychiatry, obstetrics, pediatrics, and lactation services is essential to support shared decision-making, optimize safety, and sustain treatment gains beyond the immediate postpartum period.[25,31]

Cost, accessibility, and variability in health system infrastructure are critical determinants of equitable implementation of rapid-acting treatments for postpartum depression. Brexanolone, while effective, is associated with substantial cost and requires access to REMS-certified facilities with continuous monitoring, limiting availability primarily to tertiary care centers.[11,13] In contrast, zuranolone offers improved outpatient feasibility but may still be constrained by medication cost, insurance coverage variability, and the need for careful safety monitoring.[11, 16] Access to electroconvulsive therapy and rTMS is similarly influenced by regional resource availability, workforce capacity, and institutional expertise, which may disproportionately affect underserved populations.[20,23,29] Structural disparities in maternal mental health care, including geographic barriers, insurance limitations, and fragmented care delivery, further contribute to inequities in access to advanced treatments.[28] Addressing these challenges will require system-level strategies, including expansion of perinatal mental health services, integration of psychiatric care into obstetric settings, and policy efforts to improve coverage and accessibility of evidence-based treatments.

Importantly, rapid symptom improvement should not be conflated with illness resolution. PPD is frequently recurrent, and relapse prevention requires longitudinal follow-up, psychosocial support, sleep stabilization, and, when indicated, maintenance pharmacotherapy.[31] Extending mental health care beyond the conventional 6-week postpartum window is critical to ensuring durable recovery and minimizing adverse maternal and infant outcomes.[31]

Rapid-acting treatments have expanded the therapeutic options for PPD, addressing the urgent need for timely symptom relief in moderate-to-severe illness. Neuroactive steroids represent a significant advance by targeting postpartum-specific neurobiology, with brexanolone establishing efficacy and zuranolone improving outpatient feasibility. ECT remains essential for severe and life-threatening presentations, while other somatic and emerging interventions continue to evolve. Optimal use of these interventions depends on thoughtful patient selection, robust safety monitoring, and sustained continuity of care beyond the immediate postpartum period. Continued research and equitable access will be essential to fully realize the clinical potential of rapid-acting therapies in perinatal psychiatry.

No editorial assistance or commercial support was received for the preparation of this manuscript.

No external funding was received for the preparation of this manuscript.

Corresponding Author:
Aditi Sharma
Department of Psychiatry
The Wright Center for GME, Scranton, PA, USA
Email: asv3096@gmail.com

Co-Author:
Vinod Sharma
Department of Psychiatry
Geisinger School of Medicine, Scranton, PA, US

Vinod Sharma conceptualized the study, conducted the literature review, and drafted the initial manuscript. Aditi Sharma contributed to the literature review, critical revision of the manuscript, and refinement of clinical content. Both authors approved the final version of the manuscript and agree to be accountable for all aspects of the work.

Not applicable

The authors declare that they have no conflicts of interest related to this work.

Vinod Sharma serves as the guarantor of this work and takes responsibility for the integrity of the content and the accuracy of the information presented.  

https://doi.org/10.63096/medtigo3061312

Sharma V, Sharma A. Rapid-Acting Treatments for Postpartum Depression: From Neurosteroids to Clinical Implementation: A Narrative Review. medtigo J Pharmacol. 2026;3(1):e3061312. doi:10.63096/medtigo3061312 Crossref